- Palisade Bio, Inc. announced the closing of its underwritten public offering on **October 02, 2025**, raising approximately **$138 million** in gross proceeds, including the full exercise of the over-allotment option.  **[1357459_b848e1a0a89b4953a844fd7ad10ca0a8_0]** 
- The offering comprised **197,154,844 shares** of common stock (or common stock equivalents) at a public offering price of **$0.70 per share**.  **[1357459_b848e1a0a89b4953a844fd7ad10ca0a8_0]** 
- The proceeds are intended to support the upcoming **Phase 2 clinical development program for PALI-2108 in Ulcerative Colitis**.  **[1357459_b848e1a0a89b4953a844fd7ad10ca0a8_0]** 
- The offering was led by B Group Capital and Columbia Threadneedle Investments, with significant participation from other investors.  **[1357459_b848e1a0a89b4953a844fd7ad10ca0a8_0]**

Palisade Bio closes $138 million public offering

- Palisade Bio, Inc. (PALI) announced the pricing of an underwritten public offering of **171,440,559** shares of its common stock (or common stock equivalents) at a public offering price of **$0.70** per share.  **[1357459_e233732197a2475097c08f6ec43f91a0_0]** 
- The offering is expected to generate approximately **$120 million** in gross proceeds, before deductions.  **[1357459_e233732197a2475097c08f6ec43f91a0_0]** 
- The underwriters have been granted a 45-day option to purchase up to an additional **25,714,285** shares of common stock.  **[1357459_e233732197a2475097c08f6ec43f91a0_0]** 
- The offering is anticipated to close on or about **October 2, 2025**.  **[1357459_e233732197a2475097c08f6ec43f91a0_0]**

PALISADE BIO (PALI)